CCompliment
Compliment is a Madrid-based personalized nutrition venture offering monthly subscription supplements tailored to individual health data, gathered via a health questionnaire (BASIC plan) or blood test analysis (PRO plan), delivered in granulated form for better absorption. It is a venture built and incubated by Byld, Spain's corporate venture builder, under its "Genesis" model (Byld validates the venture internally before a corporate partner joins later); as of 2025 it is still listed as "Building" in Byld's portfolio.
SectorsHealthtech, Nutrition, D2C Subscription, Wellness
Start-up MapHealthtech & Bio › Consumer & telehealth services
Founders
No names on record yet.
Global models 5
VViome
United States · www.viome.com ↗
Sells a monthly subscription of precision supplements formulated from the customer's own at-home biological test results, the same data-to-personalised-supplement model as Compliment's PRO plan.
~$175MComparable
ZZOE
United Kingdom · zoe.com ↗
A consumer subscription that turns at-home biomarker testing into personalised nutrition advice and its own supplement products, sold direct to consumers.
~$120MComparable
C
Care/of
United States · takecareof.com ↗
Pioneered the direct-to-consumer monthly subscription of vitamin packs built from an online health questionnaire, matching Compliment's BASIC plan; Bayer later took majority control.
~$75MComparable
InsideTracker
United States · www.insidetracker.com ↗
Runs blood-test analysis for consumers and turns the results into personalised nutrition and supplement recommendations on a paid plan, close to Compliment's blood-test PRO tier.
~$30MComparable
RRootine
United States · www.rootine.co ↗
Sells a monthly subscription of personalised vitamins formulated from a questionnaire plus optional blood and DNA tests, almost exactly Compliment's two-tier model.
~$10MComparable
In the same niche 60 others
See all in the Start-ups Map →Notes: Most funded first
Investors 1
Open as list →Funding rounds
No announced rounds on record.
News
No coverage on record yet.






